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RESEARCH Open Access
Derivation and validation of clinical
phenotypes for COPD: a systematic review
Lancelot M Pinto1,2, Majed Alghamdi1,2, Andrea Benedetti2,3, Tasneem Zaihra4,5, Tara Landry6
and Jean Bourbeau1,2,7*
Abstract
Background: The traditional classification of COPD, which relies solely on spirometry, fails to account for the
complexity and heterogeneity of the disease. Phenotyping is a method that attempts to derive a single or
combination of disease attributes that are associated with clinically meaningful outcomes. Deriving phenotypes
entails the use of cluster analyses, and helps individualize patient management by identifying groups of individuals
with similar characteristics. We aimed to systematically review the literature for studies that had derived such
phenotypes using unsupervised methods.
Methods: Two independent reviewers systematically searched multiple databases for studies that performed
validated statistical analyses, free of definitive pre-determined hypotheses, to derive phenotypes among patients
with COPD. Data were extracted independently.
Results: 9156 citations were retrieved, of which, 8 studies were included. The number of subjects ranged from 213
to 1543. Most studies appeared to be biased: patients were more likely males, with severe disease, and recruited in
tertiary care settings. Statistical methods used to derive phenotypes varied by study. The number of phenotypes
identified ranged from 2 to 5. Two phenotypes, with poor longitudinal health outcomes, were common across
multiple studies: young patients with severe respiratory disease, few cardiovascular co-morbidities, poor nutritional
status and poor health status, and a phenotype of older patients with moderate respiratory disease, obesity,
cardiovascular and metabolic co-morbidities.
Conclusions: The recognition that two phenotypes of COPD were often reported may have clinical implications for
altering the course of the disease. This review also provided important information on limitations of phenotype
studies in COPD and the need for improvement in future studies.
Keywords: COPD phenotypes, Phenotypes, Cluster analysis, Systematic review
Background
Chronic Obstructive Pulmonary Disease (COPD) is the
4th leading cause of mortality worldwide, and causes sig-
nificant morbidity [1,2]. Criteria have been developed to
diagnose and grade the severity of COPD based on the
post-bronchodilator FEV1 [3]. However, these criteria fail
to account for the complexity and heterogeneity of the
disease, variable symptomatic manifestations, progres-
sion and prognosis of the disease. With progress in the
understanding of the disease, and developments in the
fields of radiology, genetics, and statistical analyses,
identifying phenotypes of the disease with the aim of in-
dividualized treatment has now gained significance.
A COPD phenotype has been defined as “A single or
combination of disease attributes that describe differ-
ences between individuals with COPD as they relate to
clinically meaningful outcomes (symptoms, exacerba-
tions, response to treatment, speed of progression of the
disease or death)” [4]. Identifying such phenotypes en-
tails use of statistical techniques such as cluster analysis
[5]. The goal of cluster analysis is to assign subjects to
groups, where subjects in the same cluster are more
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similar to each other than they are to subjects in other
groups.
This review systematically searches the available litera-
ture to identify studies that have derived clinical pheno-
types in COPD using validated statistical methods, free
of definitive pre-determined hypotheses. We aimed to
summarize such studies, and the robustness of findings,
by identifying the combination of disease attributes in
patients with COPD, over and above the traditional spi-
rometric classification of disease, that describe differ-
ences between individuals as they relate to clinically
meaningful outcomes. We also aimed to identify the lim-
itations of the studies and what needed to be done to
improve this field of research.
Methods
A detailed protocol was written prior to starting the re-
view, which identified the key question, and the criteria
for the systematic review. We used the Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis
statement [6] as the template for reporting the review.
We searched the literature for studies that enrolled pa-
tients with COPD, as defined by GOLD criteria [3], in
which unsupervised (hypothesis-free) cluster analyses
were used to derive clinical phenotypes as they related
to clinically meaningful outcomes.
Search strategy
The following databases were searched for relevant stud-
ies: MEDLINE (via OvidSP 1946 to 22/Apr/2013; via
PubMed 1946 to 22/Apr/2013); Embase Classic + Embase
(via OvidSP 1947 to 19/Apr/2013); BIOSIS Previews (via
OvidSP 1969 to 2013 Week 20); Web of Science (via
ThomsonReuters 1996 to 22/Apr/2013); Scopus (via
Elsevier 1996 to 22/Apr/2013); CENTRAL (via Cochrane
Library). The search strategy used text words and relevant
indexing to answer the following question: What are the
different phenotypes of COPD that have been derived,
based on subject characteristics? The full MEDLINE strat-
egy (Appendix 1) was applied to all databases, with modifi-
cations to search terms as necessary. Further studies were
identified in Web of Science and Scopus (02/Oct/2013) by
carrying out by citations searches for studies citing included
studies, as well as by examining their reference lists. The
Medline strategy was rerun prior to submission (two rele-
vant studies were found, one of which was included).
Selection of studies
We selected studies that included at least 50 patients who
were 18 years and above, and in which a statistical method
was used to identify clusters of subjects. We excluded ab-
stracts, reviews and commentaries. Studies that exclusively
enrolled subjects with alpha-1 antitrypsin deficiency or
those that tested single risk factors, including genetic
polymorphisms, for association with outcomes in COPD
were excluded. Studies that tested empirically defined phe-
notypes without an analytical justification of these pheno-
types, and those that did not analyze the association of the
derived clusters with clinically meaningful outcomes were
also excluded.
Data extraction and consensus
Two reviewer authors (LMP and MA) independently
scrutinized titles and abstracts for eligibility. Citations
deemed relevant by either reviewer were selected and
papers retrieved for full-text review. Each eligible article
was independently assessed by two reviewers (LMP and
MA). Disagreements were resolved by discussion be-
tween the reviewers. Study quality was assessed using
the Strengthening the Reporting of Observational studies
in Epidemiology (STROBE) checklist [7].
The two reviewer authors (LMP and MA) independ-
ently extracted data from each study using a data extrac-
tion form. Disagreements were resolved by discussion.
Data were extracted for various characteristics, including
the following: author, publication year, study design,
number of participants, criteria for inclusion and exclu-
sion, statistical methods for cluster analysis and out-
comes assessed.
Statistical analysis
Descriptive statistics for the clinical features most com-
monly used in the routine care of COPD patients were
collected and tabulated from the included studies. Due
to significant heterogeneity in selection of patients, clus-
ter analyses and derived phenotypes, pooling of results
was not deemed appropriate.
Results
Studies selected for the systematic review
We identified 9156 citations, of which 4068 unique
published articles were identified after exclusion of du-
plicate articles. After screening titles and abstracts, 284
studies were found to satisfy the criteria for further re-
view and their full-texts were retrieved. After full-text
review, 276 studies were excluded for various reasons,
and 8 studies (7 observational studies, one study with
data pooled from two randomized controlled trials)
were included in the systematic review. Figure 1 sum-
marizes the selection criteria for the included studies.
In the 8 studies identified [8-15], all conducted in Europe
and USA, the median sample size included in the analyses
was 332 subjects (range 213-1543). Of the 7 studies that de-
scribed the setting, only one study had a subset of its en-
rolled subjects recruited from a community-based lung
cancer screening study [10]; all the other studies were con-
ducted in a university-based tertiary care setting. A sum-
mary of the study characteristics of the included studies
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can be found in Table 1; a more detailed description can be
found in the online supplement, Additional file 1: Table S1.
Studies reporting derivation of phenotypes for COPD that
were excluded
We excluded 8 studies that involved the derivation of phe-
notypes for COPD. Five studies were excluded as none of
the studies analyzed the association of the derived pheno-
types with any clinically meaningful outcomes. The two
studies by Paoletti et al. [16] and Pistolesi et al. [17] derived
a set of 9 variables to predict airways obstructive or paren-
chymal destructive phenotypes based on cluster analysis
used on computerized tomography (CT) parameters. The
study by Camiciottoli et al. used principal component ana-
lysis to derive 2 variables that represented the phenotype
(airway obstruction versus parenchymal destruction) and
severity of the disease using CT scans, and then used
multivariable regression to derive a set of variables to pre-
dict the two PCA-transformed variables [18]. Roy et al. [19]
performed principal component analysis to derive four
components to explain the variability in the dataset of 127
COPD patients. A recent study by Fens et al. [20] used fac-
tor analysis followed by k-means cluster analysis to derive
four phenotypes for COPD using clinical, CT scan and
breathomics-derived variables. We also excluded 3 studies
[21-23] as they included subjects with both asthma and
COPD, and in addition, did not report an association with
clinical outcomes.
COPD phenotyping in the selected studies
There was heterogeneity in the patient characteristics
across studies. One study only included patients with a
post-bronchodilator FEV1 ≤ 45% predicted [11], one study
included patients with a pre-bronchodilator FEV1 ≤ 45%
Figure 1 PRISMA flow diagram. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097. For more
information, visit www.prisma-statement.org.
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Table 1 Characteristics of the included studies of clinical phenotypes for COPD
Study, country, period Setting, design Inclusion criteria Number included in the
analysis/ number eligible
Reason for exclusion Difference between included
and excluded patients
Burgel et al. (2010), France,
Jan 2005 - Aug 2008
Pulmonary units in university
hospitals, cross-sectional
Stable COPD§ 322/584 (55%) Missing/incomplete data Significant difference in sex
distribution
Burgel et al. (2012), France,
Jan 2005 - June 2009
Pulmonary units in university
hospitals, prospective cohort
Stable COPD§ 303/584 (52%) Missing/incomplete data Significant difference in sex
distribution
Burgel et al. (2012), Belgium,
Outcome assessed in Jan 2010
2 cohorts - Leuven university hospital
COPD outpatient clinic, and from the
NELSON study: community-based
randomized lung cancer screening
study, prospective cohort
• Smoking history ≥ 15 pack-years and
age > 50 years (for the NELSON
study) COPD (for the hospital cohort)
527/649 (81%) - 374/495
from COPD clinic, 153/154
from NELSON study
Missing/incomplete data Significant difference in sex,
age, FEV1% predicted, BMI and
follow-up time
Cho et al. (2010), USA 17 university-based clinics, cross-
sectional
• Self-identified white subjects
Physician-diagnosed COPD FEV1 ≤
45% predicted Hyperinflation on PFT
Bilateral emphysema on CT scan
308/1220 (28%) Missing/incomplete data Significant difference in lung
function parameters, 6MWD,
PaCO2
DiSantostefano et al. (2013),
USA, Canada 2004-2005
Data pooled from two studies
conducted across 98, and 94
research sites, respectively (setting
not specified), randomized controlled
trials
• ≥40 years Clinical history of COPD
Pre-bronchodilator FEV1 ≤ 50% pre-
dicted, FEV1/ FVC ratio ≤ 0.7 Smok-
ing history ≥10 pack-years
Documented history of ≥1 moder-
ate/severe COPD exacerbations in
the previous year
1543/1579 (98%) Protocol violations Not reported
Garcia-Aymerich et al.
(2011), Spain, Jan 2004 -
March 2006
9 teaching hospitals, prospective
cohort
• Patients hospitalized for the first time
with a COPD exacerbation COPD,
diagnosed 3 months after discharge,
when clinically stable
342/604 (57%) Non-participation (213
patients refused, 23
patients discharged
before the interview, 12
deaths, 14 lost to follow-
up)
Significant difference in
smoking status and a
diagnosis of congestive heart
failure
Spinaci et al. (1985),
Italy, 1979-1980
University out-patient clinic, cross-
sectional
Stable, severe COLD: FEV1 < 1.5 L and
(ratio between FEV1/FVC <0.6
532 Not reported Not reported
Vanfleteren et al. (2013),
Netherlands, Nov 2007-
Nov 2010
Tertiary care referral center for
pulmonary rehabilitation program,
cross-sectional
• Moderate to very severe COPD
(GOLD stages II–IV) 40–80 years
Clinically stable
213 Not reported Not reported
§COPD defined by a post-bronchodilator FEV1/FVC ratio <0.7.
BMI – body mass index, 6MWD – six minute walk distance, PaCO2- Partial pressure of carbon dioxide in arterial blood, FEV1 – forced expiratory volume, 1 second, FVC-forced vital capacity, PFT – pulmonary
function test.
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predicted [12] and one study only included subjects
with GOLD 2-4 [15]. GOLD 1 subjects were under-
represented in the studies that reported the classification
of subjects by GOLD [8-10]. Women were under-
represented across studies too; the proportion of women
ranged from 7% [13] to 46% [12]. Table 2 summarizes the
characteristics of the subjects in the selected studies for
the systematic review; a more detailed description can
be found in the online supplement, Additional file 1:
Table S2.
There was significant heterogeneity in the methods
used for cluster analysis, these have been summarized
in Table 3, and a detailed summary of the variables in-
cluded in each analysis is reported in the online supple-
ment, Additional file 1: Table S3. None of the studies
validated the derived phenotypes in an external cohort
for clinically meaningful outcomes. Three studies pro-
spectively validated the phenotypes with mortality data
of the cohort from which the phenotypes were derived
[9,10,13], and one of these also analyzed hospital ad-
missions [13]. One of the studies [12] pooled the data
from two randomized-controlled trials [24,25] to
analyze the change in the frequency of exacerbations of
individuals who were randomized to receive salme-
terol/fluticasone propionate (SFC) compared to those
who received salmeterol alone (SAL), and whether this
response varied based on the phenotypes that were de-
rived. The other studies validated the derived phenotypes
with predicted mortality scores. These have been summa-
rized in Table 3.
Table 4 provides a summary of the derived pheno-
types and their associations with studied outcomes. A
more detailed description can be found in the online
supplement, Additional file 1: Table S4. The number of
phenotypes ranged from 2 to 5. Five of the studies de-
scribed a phenotype of younger individuals with severe
respiratory disease with a low prevalence of cardiovascular
co-morbidities, high prevalence of poor nutritional status
and poor health status [8-11,15]. In two of these studies,
women were significantly over-represented in this pheno-
type [10,15]. A similar phenotype was reported in 2 other
studies [13,14], but neither of the studies reported these
patients to be younger than the rest of the cohort. Subjects
with this phenotype had poor outcomes across the studies.
All studies reported a phenotype of older individuals with
moderate respiratory disease, and a high prevalence of
obesity. In addition, 6 studies reported subjects with this
phenotype to have an increased prevalence of cardiovascu-
lar and metabolic co-morbidities and inflammatory
markers [8-10,12,13,15]. Subjects with this phenotype
were reported to have a worse prognosis that the individ-
uals with comparable age and respiratory disease status,
and, in the study by DiSantostefano et al [12], they were
found to have an improvement of prognosis with respect
to a decrease in the frequency of exacerbations when
treated with SFC, rather than SAL alone.
Assessment of quality of studies
The 8 studies were in compliance with most of the items
on the STROBE checklist. There were methodological
limitations with some of the studies. Only one study re-
ported a rationale for the sample size [13]. Two studies
did not report numbers of individuals at each stage of
the study, nor used a flow diagram [14,15]. Only two
studies conducted sensitivity analyses: one tested the ro-
bustness of the data to using the lower limit of normal
(LLN) instead of the fixed ratio for the diagnosis of
COPD [8], and the other repeated the cluster analysis
using an alternative method, and also analyzed the re-
sults in subsets of included participants [13]. Only two
studies imputed missing values for variables, one using
the median for continuous variables, and the most fre-
quent value for categorical variables [12], and the other
using multiple imputation using chained equations [13].
One study reported the validation of the phenotypes
with contingency tables, but failed to report any specific
details [14].
Discussion
This systematic review of the literature for COPD
phenotype studies using unsupervised (free of definitive
pre-determined hypotheses) statistical analyses to derive
clusters associated with clinically relevant outcomes
yielded 8 studies with significant heterogeneity in the se-
lection of subjects, statistical methods used and out-
comes validated. Despite these differences, two clinical
phenotypes were consistently found across most studies,
and may have clinical implications.
One of the phenotypes that describe individual been
younger with severe respiratory disease, having a low
probability of cardiovascular co-morbidities, high preva-
lence of poor nutritional status and poor health status
with poor longitudinal health outcomes may be import-
ant for two reasons. Firstly, although the derivation of
phenotypes was cross-sectional, it is likely that such in-
dividuals experience a rapid decline in lung function,
and therefore, recognizing this phenotype at a younger
age and treating the disease aggressively along with mea-
sures to support smoking cessation could have import-
ant prognostic implications. Secondly, given the low
prevalence of cardiovascular co-morbidities, it is likely
that such individuals would be good candidates for lung
transplantation. Longitudinal cohort studies that include
younger patients early in the course of their disease, and
follow them closely to understand the differential pro-
gression of disease would be vital to a better understand-
ing of this phenotype. Two of the studies found a high
proportion of women in the sub-group of individuals with
Pinto et al. Respiratory Research  (2015) 16:50 Page 5 of 13
Table 2 Characteristics of subjects in the included studies of clinical phenotypes for COPD
Study Classification of patients based
on GOLD stage, n (%)
FEV1 (% predicted),
mean (SD)§
Age, mean (SD)§ Proportion males (%)§ Smoking exposure,
pack years, mean (SD)§
MMRC score,
mean (SD)§
Burgel et al. (2010) GOLD 1 - 21 (6.5)
GOLD 2 -135 (42)
GOLD 3 -107 (33)
GOLD 4 - 59 (18)
GOLD 1 - 85 (82-86)
GOLD 2 - 65 (59-71)
GOLD 3 - 40 (34-45)
GOLD 4 - 25 (21-29)
GOLD 1 - 66 (58-75)
GOLD 2 - 66 (58-72)
GOLD 3 - 64 (57-73)
GOLD 4 - 63 (58-72)
GOLD 1 - 71
GOLD 2 - 79
GOLD 3 - 71
GOLD 4 - 85
GOLD 1 - 41 (28-56)
GOLD 2 - 42 (26-55)
GOLD 3 - 38 (25-50)
GOLD 4 - 44 (30-72)
GOLD 1 - 1 (0-1)
GOLD 2 - 1 (1-2)
GOLD 3 - 2 (1-3)
GOLD 4 - 3 (2-4)
Burgel et al. (2012) Same as above Same as above Same as above Same as above Same as above Same as above
Burgel et al. (2012) GOLD 1 - 120 (22.8)
GOLD 2 -169 (32.1)
GOLD 3 -149 (28.3)
GOLD 4 - 89 (16.9)
GOLD 1 - 93 (87-103)
GOLD 2 - 64 (57-71)
GOLD 3 - 40 (36-44)
GOLD 4 - 24 (20-28)
GOLD 1 - 62 (58-67)
GOLD 2 - 68 (61-74)
GOLD 3 - 68 (62-75)
GOLD 4 - 61 (58-65)
GOLD 1 - 80
GOLD 2 - 79
GOLD 3 - 78
GOLD 4 - 72
GOLD 1 - 43 (32-55)
GOLD 2 - 47 (34-61)
GOLD 3 - 50 (32-64)
GOLD 4 - 46 (33-60)
GOLD 1 - 0 (0-1)
GOLD 2 - 1 (0-2)
GOLD 3 - 2 (1-3)
GOLD 4 - 3 (1-3)
Cho et al. (2010) Not reported. Only subjects with
GOLD stages 3 and 4 included
28.3 (7.33) 67.4 (6.08) 197 (64) 67.4 (30.4) Not reported
DiSantostefano et al. (2013) Not reported. Only subjects with
pre-bronchodilator FEV1 ≤ 50%
predicted included
33.6 (25 – 41.9) 65 (59-72) 833 (54) 52 (40-77), 633 (41%)
current smokers
Not reported
Garcia-Aymerich et al. (2011) Not reported 52.4 (16.2) 67.9 (8.6) 318 (93) Not reported, 109 (32.9%)
current smokers
2 (2-3)
Spinaci et al. (1985) Not reported, all subjects had a
FEV1/VC < 0.6
FEV1/VC 41.06 (0.39) 59.5 (9.8) 398 (75) Not reported, 274 (51.5%)
current smokers
Not reported
Vanfleteren et al. (2013) Not reported. Only subjects
with GOLD stages 2 – 4 included
51.2 (16.9) 63.6 (7) 59 46 (26) 2.1 (1.09)
§The studies by Burgel et al. and the study by DiSantostefano et al. report median (inter-quartile range).
MMRC score – modified medical research council score for assessing degree of shortness of breath, SD – standard deviation.
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this phenotype, and a stronger pattern might emerge if
more women are included in such studies. This phenotype
was also associated with a lower height in one study [13],
and the authors hypothesized that an impaired in-utero
and childhood lung growth may have been a contributing
factor to the severity of disease. This association needs to
be further validated.
The other phenotype of older individuals with moderate
respiratory disease, and a high prevalence of obesity, and
increased prevalence of cardiovascular and metabolic co-
morbidities and inflammatory markers is important as
such individuals appear to have worse health outcomes
than individuals with comparable respiratory disease with
fewer co-morbidities. Contrary to the hypothesis of a
“chronic systemic inflammatory syndrome” [26] that pro-
poses a systemic inflammation attributable to COPD,
Garcia-Aymerich et al. [13] found that bronchial inflam-
matory markers were not associated with systemic inflam-
matory markers. This suggests that the worse health
outcomes might be caused by the co-morbidities, and
consequently, screening for, and optimally treating the co-
morbidities might be associated with better health
outcomes. The study by DiSantostefano et al. also found
that patients with this phenotype had a decreased fre-
quency of moderate/severe exacerbations when treated
with SFC, when compared to those with the same pheno-
type randomized to treatment with SAL alone [12].
The study by Vanfleteren et al. [15] identified a pheno-
type with a very high prevalence of anxiety and depression.
A third of such patients had a myocardial infarction, and
as suggested by the authors, is consistent with reports on
anxiety being the strongest predictor of mortality in
COPD [27]. The study by DiSantostefano et al. also found
that a high proportion of individuals in the group with car-
diovascular comorbidities were on psycholeptic drugs
[12,14]. This is important as it is well established that de-
pression and anxiety adversely affect prognosis in COPD,
conferring an increased risk of exacerbation and possibly
death [28]. Conversely, COPD also increases the risk of
developing depression. Future studies should therefore
screen patients with COPD for psychiatric disorders for a
better understanding of this phenotype.
The present GOLD classification of COPD acknowl-
edges the complexity of the disease, and has included
Table 3 Statistical methods used for cluster analysis and outcomes tested in the included studies of clinical phenotypes
for COPD
Study Number of variables selected for
analysis, method of selecting
variables
Statistical method used for
identifying phenotypes
Outcome tested
Burgel et al. (2010) 8 variables, expert opinion Cluster using k-means after variable
reduction using PCA
BOD§ index
Burgel et al. (2012) 8 variables, expert opinion Cluster using k-means after variable
reduction using PCA
Mortality rates after 3.35 years
of follow-up
Burgel et al. (2012) 18 variables, expert opinion Hierarchical clustering with Wards method
after variables reduction using PCA and MCA
Mortality rates after 17.2
months of follow-up
Cho et al. (2010) 43 variables (including 12 SNPs
from 5 genes), expert opinion, and
selection of genes included in
previous genetic association studies
Cluster using k-means after variable
reduction using factor analysis
Exacerbations/year over 3.3
years (retrospective)
DiSantostefano et al. (2013) 36 variables analyzed, co-linear
variables dropped, expert opinion
Tree-based supervised cluster analysis
using modified recursive partitioning
Decreased annual rate of
exacerbations with SFC
compared to SAL
Garcia-Aymerich et al. (2011) 224 variables, all variables collected
(after excluding those with additive
relationships or resulting from
categorizations)
Cluster using k-means clustering
method (PKM)
Admissions and mortality rates
during a 4-year follow-up
Spinaci et al. (1985) 4 variables, expert opinion Cluster using k -means clustering
method (PKM)
Analysis of contingency tables
Vanfleteren et al. (2013) 13 variables, based on “clinical
relevance and methodological
possibilities to objectify the
comorbidities”
Self- organizing maps (SOMs, or Kohonen
maps) used to order patients by their
overall similarity with regards to comorbidities.
Clusters generated using a hybrid algorithm
that applied classical hierarchical method of
Ward on top of the SOM topology.
Updated BODE¶ index,
Framingham 10-year risk
§BOD index –Body mass index (BMI), obstruction (FEV1% pred) and dyspnoea evaluated on the modified Medical Research Council (MMRC) scale). Celli B, Jones P,
Vestbo J, et al. The multidimensional BOD:association with mortality in the TORCH trial. Eur Respir J 2008; 32: Suppl. 52, 42 s.
¶BODE index - Body mass index (BMI), obstruction (FEV1% pred), dyspnoea evaluated on the modified Medical Research Council (MMRC) scale), and exercise
capacity on the 6-minute walk test. Celli B, et al. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive
Pulmonary Disease. N Engl J Med 2004; 350:1005-1012.
PCA – Principal component analysis, MCA – Multiple component analysis.
Pinto et al. Respiratory Research  (2015) 16:50 Page 7 of 13
Table 4 Description of the derived phenotypes and association with outcomes analyzed in the included studies of clinical phenotypes for COPD
Study Phenotype 1 Phenotype 2 Phenotype 3 Phenotype 4 Phenotype 5
Burgel et al. (2010) Phenotype • Young individual Very severe
respiratory disease Frequent
exacerbator Poor nutritional
status Low prevalence of
cardiovascular comorbidities
High prevalence of
depression and very poor
HRQoL
• Older individual Mild
respiratory disease High
prevalence of overweight Low
prevalence of cardiovascular
comorbidities and depression
Mildly impaired HRQoL
• Young individual Moderate
respiratory disease Normal
nutritional status Low
prevalence of cardiovascular
comorbidities and depression
Moderately impaired HRQoL
• Older individual Moderate
respiratory disease
Frequent exacerbator High
prevalence of overweight
High prevalence of
cardiovascular
comorbidities and
depression Poor HRQoL
N (%) 44 (13.7) 89 (27.6) 93 (28.9) 96 (29.8)
Outcome analyzed- BOD score* 5 (4-6) 1 (1-2) 3 (2-3) 4 (3-6)
Burgel et al.§ (2012) Outcome analyzed- crude
mortality rate
15 (35%) 7 (8%) 17 (20%) 21 (25%)
Outcome analyzed- age at
death, median, IQR
62 (58-68) 77 (66-83) 67 (58-69) 76 (74-79)
Age-adjusted mortality risk
(Cox model)
8.35 (3.13,22.22) v Phenotype 2
1.91 (0.94,3.06) v Phenotype 3
3.18 (1.37,7.4) v Phenotype 4
Reference group with lowest
mortality risk
4.33 (1.73,11.06) v Phenotype 2
1.67 (0.78, 3.57) v Phenotype 4
2.63 (1, 6.25) v Phenotype 2
Burgel et al. (2012) Phenotype • Young individual Mild to
moderate airflow limitation
Absent or mild emphysema
Absent or mild dyspnea
Normal nutritional status
Limited comorbidities
• Young individual Over-
representation of women in
the group Severe airflow limi-
tation Marked emphysema
and hyperinflation Low BMI
Severe dyspnea Impaired
HRQoL Osteoporosis, muscle
weakness highly prevalent
Diabetes and cardiovascular
comorbidities less prevalent.
• Older individual Mostly male
Moderate to severe airflow
limitation Less severe
emphysema than subjects in
Phenotype 2 Higher
prevalence of bronchial
thickening Higher prevalence
of obesity, diabetes and
cardiovascular comorbidities
N (%) 219 (41.5) 99 (18.8) 209 (39.7)
Outcome analyzed- crude
mortality rate
1 (0.5%) 20 (20.6%) 29 (14.3%)
Age-adjusted mortality risk
(Cox model)
Reference group with lowest
mortality risk
47.5 (6.3,358.6) v Phenotype 1
3.3 (1.5,7.2) v Phenotype 3
14.3 (1.9,110.3) v Phenotype 1
Cho et al. (2010) Phenotype • Emphysema predominant
Lower BMI Fewer pack-years
of smoking Higher TLC, lower
DLCO Lower 6MWD and max-
imum work
• Milder severity, fewer
symptoms of dyspnea Fewer
exacerbations, despite being
of slightly older age
Bronchodilator responsive
Higher BMI Greater FVC and
DLCO Lower PaCO2 Higher
6MWD and maximum work,
• Less emphysema and lower
wall thickness (similar to
Phenotype 2) Lower FEV1, less
bronchodilator
responsiveness, more
dyspnea compared to
Phenotype 2 despite a
relatively younger age
• Airway predominant,
highest airway thickness
Higher BMI Lower TLC Less
severe emphysema Lower
PaO2 and lower 6MWD
N (%) 66 (21.4) 102 (33.1) 88 (28.6) 52 (16.9)
Outcome analyzed- exacerba-
tions (retrospectively over 3.3
years)
0.19 0 0.19 0.15
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Table 4 Description of the derived phenotypes and association with outcomes analyzed in the included studies of clinical phenotypes for COPD (Continued)
DiSantostefano
et al. (2013)
Phenotype • Treated with diuretics Higher
BMI Fewer current smokers
Frequent moderate
exacerbations Higher use of
cardiac medications and
psycholeptics
• Not treated with diuretics
Lower FEV1 Highest FEV1
reversibility post-
bronchodilator Fewer propor-
tion of subjects on cardiac
medications and psycholeptics
• Not treated with diuretics
Higher proportion of current
smokers Higher FEV1 Lowest
FEV1 reversibility post-
bronchodilator
N (%) 454 (29) 756 (49) 333 (22)
Outcome analyzed- response
in the rate of exacerbations to
SFC as compared to SAL
Reduction in the annual rate of
moderate/severe exacerbations
among patients randomized to
SFC as compared with SAL
alone (RR = 0.56, p < 0.001);
Reduction in the annual rate of
moderate/severe exacerbations
among patients randomized to
SFC as compared with SAL
alone (RR = 0.67, p < 0.001)
No change in the annual rate
of moderate/severe
exacerbations among patients
randomized to SFC as
compared with SAL alone (RR
= 1, p not significant)
Garcia-Aymerich
et al. (2011)
Phenotype • Severe respiratory disease
Poor functional capacity
Emphysematous Few
comorbidities
• Milder respiratory disease
Preserved BMI Few
comorbidities
• Mild respiratory disease High
BMI Higher prevalence of
comorbidities and
inflammatory markers
N (%) 126 (36.9) 125 (36.5) 91 (26.6)
Outcome analyzed- ATS/ERS
severity stage adjusted - COPD
admission risk
2.89 (1.59 - 5.25) Reference group with lowest
mortality risk
1.54 (0.91 - 2.63)
Outcome analyzed- ATS/ERS
severity stage adjusted
-Mortality
2.01 (0.72 - 5.62) Reference group with lowest
mortality risk
1.55 (0.67 - 3.58)
Spinaci et al. (1985) Phenotype • Severe respiratory disease
Heavy smokers
Emphysematous Frequent
hospitalizations
• Milder respiratory disease
Preserved body weight Lower
prevalence of emphysema
Fewer hospitalizations
N (%) 189 (36) 343 (64)
Outcome analyzed- Analysis of
contingency tables
Worse prognosis of life (details
not provided)
Vanfleteren et al.
(2013)
Phenotype • Younger individuals Fewer
comorbidities Higher HRQoL
• Older individuals Higher
prevalence of cardiovascular
comorbidities Poor HRQoL
• Younger individuals Women
over-represented in the group
Higher prevalence of emphy-
sema Higher prevalence of
underweight, muscle wasting,
osteoporosis
• Predominantly male High
prevalence of obesity,
hyperglycemia,
dyslipidemia and
atherosclerosis
• Younger
individuals
• Severe
dyspnea
• High
prevalence
of anxiety
and
depression,
• Poor
HRQoL
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Table 4 Description of the derived phenotypes and association with outcomes analyzed in the included studies of clinical phenotypes for COPD (Continued)
N (%) 67 (31.4) 49 (23) 44 (21) 33 (15.5) 20 (9.4)
Outcome analyzed- Updated
BODE score**
2.4 (2.6) 3.4 (3.3) 3 (1.8) 2.6 (2.3) 3.1 (1.9)
Outcome analyzed- Framing-
ham 10-year risk, %
8.6 (6.6) 11.5 (6.6) 7.6 (6) 11.9 (7.3) 6.6 (4.5)
*BOD score – Score calculated using body mass index (BMI), obstruction (FEV1 % pred) and dyspnoea evaluated on the modified Medical Research Council (MMRC) scale).
§The study was a longitudinal analysis of outcomes for the same cohort enrolled in the study by Burgel et al. (2010)9.
**BODE score - Score calculated using body mass index (BMI), obstruction (FEV1 % pred), dyspnoea evaluated on the modified Medical Research Council (MMRC) scale), and exercise capacity on the 6-minute walk test.
HRQoL – health-related quality of life, IQR – inter-quartile range, BMI – body-mass index, TLC – total lung capacity, DLCO- diffusion capacity of the lung for carbon monoxide, 6MWD- six-minute walk distance, FVC –
forced vital capacity, PaCO2- Partial pressure of carbon dioxide in arterial blood, SFC – salmeterol/fluticasone propionate SAL - salmeterol.
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measures of risk, in addition to classification based on se-
verity of the spirometric abnormality [3]. A comparison of
the predictive ability of phenotypes and that of the present
GOLD classification with regards to clinically relevant out-
comes would help in our understanding of the disease
process, and needs to be explored by future studies.
Several methodological limitations were observed in the
studies, and the elaboration of these limitations will hope-
fully serve to guide future studies. In a biased sample, the
derived phenotypes merely reflect the bias in selection,
and not necessarily the heterogeneity of disease. Of the 7
studies that specified the setting, all [8,9,11,13-15] except
a subset on one study [10] were conducted in university-
based referral centers, and patients with mild, early dis-
ease. In most developed countries, the prevalence of
COPD in women has been reported to be comparable to
that of men in recent years [29] and it therefore appears
that women were under-represented in most included
studies. Four studies [8-11] reported missing data, and
only subjects with complete data were analyzed. This lead
to a significant proportion of patients being excluded; the
excluded patients were found to be statistically signifi-
cantly different from those who were included on several
important parameters. Strategies such as multiple imputa-
tions, employed by two studies [12,13], may be of use in
the design of future studies.
Studies used different statistical methodologies for the
derivation of phenotypes. Three studies [8-10] used prin-
cipal component analysis for reducing the dimensionality
of the data; the clinical meaningfulness of principal com-
ponents can be difficult to interpret. Cho et al. [11] used
factor analysis, followed by several clustering algorithms,
a method that is considered robust. However, the study
had a sample that was biased toward very severe disease,
and the external validity of the results needs to be tem-
pered. DiSantostefano et al. used tree-based supervised
cluster analysis using modified recursive partitioning to
derive clusters. Self-organizing maps, used in one study
[15], are a newer method that needs further validation.
A summary of the strengths and weaknesses of the vari-
ous clustering techniques can be found in a recent re-
view by the authors of this study [30]. Only one study
internally validated the clusters by splitting the dataset
for derivation and validation [12], but none of the stud-
ies validated the derived phenotypes in an external
population, limiting the validity of these derived pheno-
types. Few studies investigated the robustness of the de-
rived phenotypes to (i) statistical methods used to perform
the clustering; (ii) variables used to define the clusters. The
use of prognostic indicators such as the BODE index and
contingency tables, employed by three of the studies
[8,14,15], is far less robust than the use of clinical endpoints
to validate the phenotypes, and this limits the validity of the
results of these studies. Two of the studies included
subjects enrolled in randomized controlled trials (RCTs)
[11,12], and it is likely that the populations selected were
less heterogeneous than those based in the community, and
the studies were likely to suffer from selections biases in-
herent to RCTs. Lastly, as all of the studies derived pheno-
types with cross-sectional data; the stability of these
phenotypes over time, and the effect of medications and in-
terventions remain unknown, and needs to be studied in
prospective studies.
The strengths of this systematic review include an a
priori protocol, detailed literature search with no language
restrictions, performed by a librarian (TL), independent
review by two reviewers at every stage of the review, and
exhaustive data extraction from included studies. The in-
volvement of biostatisticians (AB, TZ) with expertise in
this research field, significantly helped our understanding
of the literature.
A major limitation of the study is the exclusion of studies
that included patients with asthma. This possibly explains
the lack of the asthma-COPD overlap phenotype [31] in
the included studies. However, the exclusion was per proto-
col, with the aim of having the systematic review focused to
answering a specific question. We also excluded studies
that tested specific hypothesis-driven, or empiric pheno-
types without a derivation study, reflecting the specific re-
search question that the review was aimed to answer.
Conclusion
This systematic review of the literature identified studies in
which two phenotypes of COPD were reported often,
representing different aspects of the disease spectrum, and
recognizing these phenotypes and treating them optimally
may have implications for altering the course of the disease.
However, the selection of specific subsets of patients, evi-
dent in the existing studies, limits the generalizability of the
results. This systematic review has provided important in-
formation on limitations of the phenotype studies in COPD
and the need for improvement in future research. There is
a need for sampling different populations in the COPD dis-
ease spectrum, to mirror the population of COPD patients
at large, including women, never smokers, and those with
mild disease. There is also a need for longitudinal studies of
patients with COPD to validate in the same cohort and to
explore sources of variability in phenotypes and their tem-
poral nature as well as to allow an iterative validation
process in which candidate phenotypes are identified before
their relevance to clinical outcome is determined.
Appendix 1: COPD Phenotypes: search strategy
(May 13th, 2013)
The following databases were searched for relevant stud-
ies: MEDLINE (via OvidSP 1946 to 22/Apr/2013; via
PubMed 1946 to 22/Apr/2013) ; Embase Classic + Embase
(via OvidSP 1947 to 19/Apr/2013); BIOSIS Previews (via
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OvidSP 1969 to 2013 Week 20); Web of Science (via
ThomsonReuters 1996 to 22/Apr/2013); Scopus (via
Elsevier 1996 to 22/Apr/2013); CENTRAL (via Cochrane
Library). The search strategy used text words and relevant
indexing to answer the following question: What are the
different phenotypes of COPD, based on subject charac-
teristics? The full MEDLINE strategy, shown below, was
applied to all databases, with modifications to search
terms as necessary.
1. exp Pulmonary Disease, Chronic Obstructive/ (20075)
2. Lung Diseases, Obstructive/ (17796)
3. exp Pulmonary Emphysema/ (13525)
4. (obstructive adj2 (pulmonary or lung$ or respirat$
or air$)).tw. (32407)
5. (chronic air$ adj2 (obstruction$ or limitation$ or
occlusion$)).tw. (1332)
6. (chronic bronch$ adj2 (obstruction$ or limitation$
or occlusion$)).tw. (90)
7. (chronic$ adj2 bronch$).tw. (12047)
8. COPD.tw. (22440)
9. COAD.tw. (185)
10. emphysema$.tw. (19592)
11. or/1-10 (81067)
12. exp Phenotype/ (202484)
13. Genetics/ (11665)
14. exp Genotype/ (268840)
15. (phenotyp$ or genotyp$).tw. (481741)
16. (clusters or clustering).tw. (107696)
17. exp cluster analysis/ (38617)
18. (cluster$ adj3 analys$).tw. (17931)
19. or/12-18 (832022)
20. 11 and 19 (2920)
21. exp Tomography, X-Ray/ (284476)
22. Tomography/ (8768)
23. exp Diagnostic Techniques, Respiratory System/
(227864)
24. exp Biological Markers/ (579344)
25. “Quality of Life”/ (106896)
26. Sickness Impact Profile/ (5735)
27. exp “Severity of Illness Index”/ (154452)
28. Disease Progression/ (92654)
29. exp Mortality/ (262597)
30. mortality.fs. (387945)
31. tomograph$.tw. (228779)
32. cine ct.tw. (132)
33. (c?t adj2 (scan$ or ray$)).tw. (65050)
34. (tomodensitomet$ or tomo densitomet$).tw. (782)
35. (xray$ or “x ray$”).tw. (216447)
36. (bronchograph$ or bronchoscop$).tw. (20406)
37. (mucocil?iary adj2 (clearance$ or transport$)).tw.
(2580)
38. ((blood or pulmonary or lung$) adj2 gas$2).tw.
(22758)
39. plethysmograph$.tw. (11082)
40. ((respiratory or ventilation) adj2 air$).tw. (2842)
41. (ergomet$ adj2 test$).tw. (2380)
42. (test$ adj2 (exercis$ or tre?dmill or stress or step
or stepping)).tw. (35120)
43. spiromet$.tw. (14294)
44. ((lung$ or respiratory or pulmonary or air$ or
bronch$) adj2 (function$ or capacit$ or compliance
$ or ventilat$)).tw. (74259)
45. ((lung$ or respiratory or pulmonary or air$ or
bronch$ or ventilation) adj2 (test$ or assess$ or
evaluat$ or measur$)).tw. (51207)
46. (breath$ adj2 work$).tw. (1554)
47. ((breath$ or respirat$ or lung$) adj2 sound$).tw.
(1284)
48. (stridor$ or rale$ or crackle$ or ronchi$ or
ronchus or wheezing$).tw. (10954)
49. (pleural adj2 rub$).tw. (31)
50. sputum.tw. (21066)
51. (qualit$ adj2 life).tw. (133643)
52. QOL.tw. (16886)
53. ((sickness or illness or disease) adj2 (impact$ or
profile$ or severity)).tw. (35074)
54. SIP.tw. (1744)
55. (exacerbat$ or deteriorat$).tw. (135724)
56. (expiratory adj3 (volume$ or flow or rate$)).tw.
(20622)
57. (“vital capacit$” adj2 timed).tw. (44)
58. (FEV or FEV1 or “FEV 1” or FEVT or “FEV T”).tw.
(21424)
59. (modified adj2 “medical research council”).tw.
(155)
60. MMRC.tw. (82)
61. (george$ adj2 “respiratory questionnaire$”).tw.
(908)
62. SGRQ.tw. (648)
63. mortality.tw. (423721)
64. or/21-63 (2631848)
65. 20 and 64 (1589)
66. limit 65 to animals (171)
67. limit 66 to humans (98)
68. 66 not 67 (73)
69. 65 not 68 (1516)
70. limit 69 to “all child (0 to 18 years)” (172)
71. limit 70 to “all adult (19 plus years)” (122)
72. 70 not 71 (50)
73. 69 not 72 (1466)
74. remove duplicates from 73 (1422)
Proceedings of the American Thoracic Society (ATS),
American College of Chest Physicians (ACCP) and the
European Respiratory Society Congress (ERS) were
searched from 2009-2012, 2003-2012 and 2006-2012,
respectively.
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